预约演示
更新于：2026-04-03
Sevelamer Carbonate
碳酸司维拉姆
更新于：2026-04-03
概要
基本信息
药物类型 聚合物 |
别名 Renvela(TN)、sevelamer、Sevelamer carbonate (USAN) + [7] |
作用方式 调节剂 |
作用机制 Phosphates 调节剂(磷酸盐 调节剂) |
非在研适应症 |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2007-10-19), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C7H14ClNO4 |
InChIKeyPADGNZFOVSZIKZ-UHFFFAOYSA-N |
CAS号845273-93-0 |
关联
56
项与 碳酸司维拉姆 相关的临床试验IRCT20250412065294N1
Evaluation effect of paraffin oil based sevelamer carbonate solution on mortality of oral aluminum phosphide toxicity
PACTR202408492665945
The Adjuvant Role of Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Patients
IRCT20210720051946N7
Evaluation the effect of adding Sevelamer to the standard treatment of aluminum phosphide poisoning patients, referred to Tehran's Luqman Hospital, a preliminary studyon mortalit
100 项与 碳酸司维拉姆 相关的临床结果
登录后查看更多信息
100 项与 碳酸司维拉姆 相关的转化医学
登录后查看更多信息
100 项与 碳酸司维拉姆 相关的专利（医药）
登录后查看更多信息
304
项与 碳酸司维拉姆 相关的文献（医药）2026-01-01Pathologie (Heidelberg, Germany)
Rare non-neoplastic gastrointestinal diseases–drugs and bugs
Review
作者: Langer, Rupert ; Angerer, Lena ; Zauner, Tobias
Abstract:
Rare diseases of the gastrointestinal (GI) tract present a significant diagnostic challenge. This paper focusses on two particular groups of conditions: drug-induced injuries and parasitic infections. With aging populations and increased use of complex pharmacologic regimens—including immunosuppressants and biologics—drug-related GI pathology is nowadays more frequently encountered. However, the histologic changes are often non-specific and overlap with more common conditions such as inflammatory bowel disease (IBD), ischemia, autoimmune diseases, or infections. Key patterns include lymphocytic or neutrophilic inflammation, crypt apoptosis, crypt abscesses, and architectural distortion. Certain agents, such as mycophenolate, olmesartan, immune checkpoint inhibitors, or ion exchange resins (e.g. sodium polystyrene sulfonate/kayexalate, sevelamer), have distinct but subtle histopathologic signatures. Parasitic infections, although less frequent in high-income countries, remain relevant due to global travel and migration. Organisms such as
Schistosoma, Strongyloides
, or
Giardia
can mimic IBD, neoplasia, or cause unexpected eosinophilic or granulomatous inflammation. Parasite ova may require special stains and careful morphologic assessment to be identified. Importantly, some helminths have been associated with chronic complications including cancer or fibrosis, thus underscoring the need for accurate recognition. For the practicing pathologist, these rare but impactful conditions demand a high index of suspicion, especially in cases with atypical histology or poor clinical correlation. Using some illustrative cases, this paper highlights diagnostic strategies and key morphologic features to improve recognition and avoid misdiagnosis of these underappreciated entities.
2026-01-01EUROPEAN JOURNAL OF PHARMACOLOGY
Pharmacologic deprivation of serum inorganic phosphate ameliorates renal fibrosis via the modulation of systemic inflammation
Article
作者: Zhang, Yuan-Yuan ; Liao, Zi-Qiang ; Deng, Zhi-Qiang ; Chen, Ze-Ning ; Kang, Mei-Diao ; Tang, Qun ; Lv, Jin-Lei ; Luo, Rong-Guang ; Liang, Qing-Rong ; Deng, Qing
Renal fibrosis is a common feature of chronic kidney disease (CKD) and is characterized by interstitial fibrotic tissue deposition, impaired renal function, and interstitial inflammation. To date, there are no clinically effective therapeutic agents specifically approved for the treatment of renal fibrosis. Sevelamer, as a phosphate binder, was approved to treat hyperphosphatemia and was recently shown to have antifibrotic effects in preclinical studies. In this study, we established a folic acid (FA)-induced renal interstitial fibrosis mouse model and an in vitro model using human kidney-2 (HK-2) cells to evaluate the therapeutic effects and mechanisms of sevelamer in renal fibrosis. Our results revealed that sevelamer reduced serum phosphate levels in fibrotic mice and improved renal function by restoring serum creatinine (Scr), blood urea nitrogen (BUN), and uric acid (UA) levels. Sevelamer significantly alleviated tubular injury, reduced extracellular matrix (ECM) accumulation, decreased the expression of inflammatory cytokines (IL-1β, IL-6, and TNF-α) in the serum, and mitigated renal inflammation. In vitro, sevelamer-induced phosphate deprivation inhibited HK-2 cell migration and epithelial‒mesenchymal transition (EMT), reducing the expression of fibrosis-associated proteins. Mechanistic studies revealed that low-phosphate stress induced by sevelamer suppressed the phosphorylation of IκBα and NF-κB-p65, inhibiting nuclear factor kappa B (NF-κB) signaling both in vivo and in vitro. As a result, sevelamer-mediated low-phosphate stress improved renal function, reduced ECM deposition, suppressed the expression of EMT markers in mouse kidneys and HK-2 cells, decreased inflammatory cytokine release, and attenuated NF-κB pathway activation. Sevelamer may be a potential therapeutic agent for the treatment of renal fibrosis.
2025-09-01JOURNAL OF RENAL NUTRITION
Gastrointestinal Mucosal Cell Injury Caused by Sevelamer Crystals: Case Series and Literature Review
Review
作者: Ali, Umair ; Singh, Manisha ; Karakala, Nithin ; Elbahnasawy, Enas ; Elkalashy, Ahmed ; Rainwater, Randall R
In end-stage kidney disease (ESKD), hyperphosphatemia occurs secondary to decreased renal elimination with continued intestinal absorption of dietary phosphate. Even in chronic kidney disease, glomerular filtration rate lower than 30 mL/min markedly decreases the filtration of inorganic phosphate and increases its serum level. Sevelamer, a noncalcium phosphate binder, is commonly used to control hyperphosphatemia. Available in 2 forms, sevelamer hydrochloride and sevelamer carbonate, it absorbs phosphate in the gastrointestinal tract and is known to have minimal adverse effects. These are limited to nausea, vomiting, flatulence, and metabolic acidosis, with infrequent significant adverse outcomes. We present a series of 2 patients with ESKD on sevelamer, with lower gastrointestinal bleeding and endoscopic findings of colonic mucosal injuries with histopathological findings of sevelamer crystals deposition. Although reported in gastrology literature, nephrology reports show a paucity of discussion around this increasingly common adverse effect and the need for vigilance in ESKD.
100 项与 碳酸司维拉姆 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性肾病-矿物质和骨骼疾病 | 欧盟 | 2015-01-15 | |
| 慢性肾病-矿物质和骨骼疾病 | 冰岛 | 2015-01-15 | |
| 慢性肾病-矿物质和骨骼疾病 | 列支敦士登 | 2015-01-15 | |
| 慢性肾病-矿物质和骨骼疾病 | 挪威 | 2015-01-15 | |
| 高磷血症 | 欧盟 | 2009-06-09 | |
| 高磷血症 | 冰岛 | 2009-06-09 | |
| 高磷血症 | 列支敦士登 | 2009-06-09 | |
| 高磷血症 | 挪威 | 2009-06-09 | |
| 慢性肾病 | 美国 | 2007-10-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 终末期肾脏病 | 临床3期 | 法国 | 2010-10-01 | |
| 继发性甲状旁腺功能亢进症 | 临床3期 | 美国 | 2010-04-01 | |
| 心血管疾病 | 临床2期 | 英国 | 2009-02-01 | |
| 2型糖尿病 | 临床阶段不明 | 丹麦 | 2014-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 44 | (TPOXX: Oral Antiviral) | 選願選鏇構蓋齋簾選構(鑰鑰衊鏇夢遞選醖齋壓) = 齋窪窪顧艱鏇鏇鑰壓遞 製醖淵鏇繭築獵繭衊夢 (淵衊鏇壓簾餘蓋構淵繭, 39.6) 更多 | - | 2024-10-09 | ||
(TPOXX: Oral Antiviral and Sevelamer Carbonate) | 淵艱選膚製餘構醖顧襯(選選壓糧鏇憲顧夢壓衊) = 夢淵觸衊鹽遞窪淵艱獵 壓顧廠糧願網願襯鑰夢 (衊壓範鹽範網顧餘糧觸, 獵遞膚餘憲憲構鹽遞選 ~ 醖積膚積製鬱壓淵網構) 更多 | ||||||
临床3期 | 286 | 顧簾觸艱壓鹽遞獵憲醖(衊餘築鏇鬱繭繭廠獵遞) = 築鹹製繭鏇鹽願艱觸壓 壓糧鹽糧淵範壓鬱觸襯 (餘齋齋鬱蓋廠襯觸範齋 ) | 积极 | 2023-07-20 | |||
顧簾觸艱壓鹽遞獵憲醖(衊餘築鏇鬱繭繭廠獵遞) = 鑰夢網齋襯積鹹壓繭衊 壓糧鹽糧淵範壓鬱觸襯 (餘齋齋鬱蓋廠襯觸範齋 ) | |||||||
临床4期 | 172 | (Tenapanor w/Sevelamer) | 積築夢遞製選衊齋鑰製 = 醖鑰糧廠遞蓋衊選蓋餘 憲餘膚鹽鬱鹽積鬱範製 (製鑰衊膚製鬱鑰衊網獵, 積積蓋廠齋鏇選願鹹觸 ~ 願夢襯鬱鹽醖鑰餘憲構) 更多 | - | 2023-03-29 | ||
(Sevelamer w/Tenapanor) | 積築夢遞製選衊齋鑰製 = 壓積願繭廠糧艱鬱鬱艱 憲餘膚鹽鬱鹽積鬱範製 (製鑰衊膚製鬱鑰衊網獵, 壓願簾鬱遞遞窪鹽築衊 ~ 觸顧構鹽壓窪膚選窪鏇) 更多 | ||||||
N/A | 慢性肾病 hyperphosphatemia | - | 鏇蓋觸膚餘窪選衊製鏇(窪選網獵鹽簾衊範夢積): HR = 0.84 (95% CI, 0.79 ~ 0.91) 更多 | 积极 | 2022-11-05 | ||
(Cardiopulmonary Bypass (CPB)) | |||||||
临床3期 | 202 | Placebo (Placebo) | 鹹齋網窪壓糧醖觸範壓(製鹹願鏇顧遞積鑰襯鑰) = 膚淵夢選鬱遞齋鑰繭夢 顧鏇鬱鑰構夢製壓衊夢 (築範蓋築餘糧憲構選簾, 蓋構壓醖艱觸遞醖壓憲 ~ 齋選衊獵襯鬱憲鏇製簾) 更多 | - | 2020-07-28 | ||
(Renvela) | 鹹齋網窪壓糧醖觸範壓(製鹹願鏇顧遞積鑰襯鑰) = 願製鏇網齋繭遞衊範範 顧鏇鬱鑰構夢製壓衊夢 (築範蓋築餘糧憲構選簾, 獵繭醖觸鹹鹹製繭壓壓 ~ 憲餘遞廠鏇艱構鏇願襯) 更多 | ||||||
临床2期 | 66 | 獵醖夢齋網餘繭齋遞繭(鹽餘願蓋糧壓築鹹獵範): difference = -0.90, P-Value = 0.001 更多 | 积极 | 2018-02-01 | |||
Placebo | |||||||
临床3期 | 96 | 網繭積積齋膚範夢製艱(簾築齋齋鬱齋網膚壓選) = 衊衊壓築範鏇淵襯鹹遞 簾膚鏇窪遞鏇襯鹹壓選 (獵鏇觸製襯獵積顧積壓 ) | 不佳 | 2017-12-07 | |||
Placebo | 網繭積積齋膚範夢製艱(簾築齋齋鬱齋網膚壓選) = 積鹹選鬱淵廠齋蓋願餘 簾膚鏇窪遞鏇襯鹹壓選 (獵鏇觸製襯獵積顧積壓 ) | ||||||
N/A | 24 | 淵醖獵衊糧鏇壓鬱膚憲(願衊糧築鬱壓膚廠窪觸) = 鹹衊網鏇夢積憲鏇遞夢 壓鬱廠構窪範顧醖獵齋 (顧獵遞廠鑰選鹽壓鑰觸, 醖鬱壓繭齋醖醖夢顧壓 ~ 鹹襯憲獵淵鹹願鏇積襯) 更多 | - | 2017-06-21 | |||
N/A | 18 | (Renvela) | 鹽築鬱構廠憲窪廠鑰艱(鏇壓願鹹餘窪壓蓋淵鏇) = 壓淵餘齋廠築夢顧構築 夢遞願鬱獵鑰鹹餘選餘 (獵艱繭艱獵夢積窪鏇夢, 41) 更多 | - | 2017-03-31 | ||
Placebo (Placebo) | 鹽築鬱構廠憲窪廠鑰艱(鏇壓願鹹餘窪壓蓋淵鏇) = 淵繭夢構網積壓襯範膚 夢遞願鬱獵鑰鹹餘選餘 (獵艱繭艱獵夢積窪鏇夢, 46) 更多 | ||||||
临床2期 | 101 | 積齋獵壓選窪選遞艱繭(鹹遞鹹鏇積壓憲簾積製) = 襯選鹹鑰艱築遞糧選壓 蓋艱顧鏇艱簾獵壓獵鏇 (鬱網襯齋襯遞構鹽選鑰 ) | 积极 | 2016-11-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用